COLUMBUS, Ohio – Physicians, veterinarians and other scientists from around the world will gather at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) Oct. 15-16 for the biennial meeting of The International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD). The conference promotes research to improve outcomes in leukemia and related diseases worldwide.
“Symposium XXIV: Molecular Approaches to Leukemia in the 21st Century: Biology, Outcome Prediction and Personalized Therapy” features lectures by a distinguished group of internationally renowned scientists and is expected to attract 400 participants to the Mershon Auditorium on the Ohio State campus.
Dr. Clara D. Bloomfield, a Distinguished University Professor at Ohio State who also serves as Cancer Scholar and Senior Adviser to OSUCCC-James, is president of the International Association. She will give opening and closing remarks.
“Leukemia is being cured more rapidly than other types of cancer, in part because leukemia cells are readily available and easier to study,” said Bloomfield. “As a result, researchers worldwide have been able to translate principles learned in leukemia to help treat other forms of cancer.”
An estimated 139,860 people in the United States will be diagnosed with leukemia, lymphoma or myeloma in 2009, and an estimated 53,240 people in the United States will die from these blood diseases this year, according to The Leukemia & Lymphoma Society.
Highlighting the symposium will be three Memorial Lectures delivered by prominent leukemia researchers:
- Dr. Rudolf Jaenisch of the Massachusetts Institute of Technology and founding member of the Whitehead Institute of Technology in Cambridge, Mass will present the Yohei Ito Memorial Lecture, “Stem Cells, Pluripotency and Nuclear Reprogramming,” at 8 a.m. Oct. 15.
- Dr. Hartmut Dohner of the University Hospital of Ulm in Ulm, Germany, will present the Kenneth McCredie Memorial Lecture, “Prognostic vs. Predictive Markers in Acute Myeloid Leukemia: Molecular Guidance to Treatment,” at 5:20 p.m. Oct. 15.
- Dr. Brian Druker of Oregon Health & Science University Knight Cancer Institute in Portland, Ore., will present the Charlotte Friend Memorial Lecture, “When Biology Guides Treatment: Chronic Myelogenous Leukemia, a Paradigm for Rational Therapies in Leukemia,” at 12:45 p.m. Oct. 16.
In addition, the following OSUCCC-James researchers will give these presentations during the symposium:
- Dr. Michael Grever, “Hairy Cell Leukemia: A Successful Model for Experimental Therapeutics in Orphan Diseases” at 8:45 a.m. Oct. 15.
- Dr. John Byrd, “Novel Therapies in Chronic Lymphocytic Leukemia” at 9:35 a.m. Oct. 15.
- Dr. Guido Marcucci, “Integration of MicroRNA and Gene Expression Profiles: Uncover Novel Molecular Subsets of Acute Myeloid Leukemia” at 8:55 a.m. Oct. 16.
- Dr. Danillo Perrotti, “Uncovering the Mechanisms of Blast Transformation in Chronic Myelogenous Leukemia” at 4:10 p.m. Oct. 16.
In 1960, the World Health Organization inaugurated the International Association and its symposia, which are held every two years at various locations worldwide. The mission of the symposia is to foster interdisciplinary approaches and develop novel experimental models to understand the disease mechanisms and design advanced treatment approaches in the fight against leukemia. For more information or to register, visit www.osuccc.osu.edu or call 614-293-3688.
The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top 20 cancer hospitals in the nation, The James (www.jamesline.com) is the 180-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only five centers in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.# # #
Medical Center Communications